Cargando…

CureVac sues BioNTech over mRNA technology

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362402/
https://www.ncbi.nlm.nih.gov/pubmed/35945444
http://dx.doi.org/10.1038/s41587-022-01442-8
_version_ 1784764717640712192
collection PubMed
description
format Online
Article
Text
id pubmed-9362402
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-93624022022-08-10 CureVac sues BioNTech over mRNA technology Nat Biotechnol News in Brief Nature Publishing Group US 2022-08-09 2022 /pmc/articles/PMC9362402/ /pubmed/35945444 http://dx.doi.org/10.1038/s41587-022-01442-8 Text en © Springer Nature America, Inc. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News in Brief
CureVac sues BioNTech over mRNA technology
title CureVac sues BioNTech over mRNA technology
title_full CureVac sues BioNTech over mRNA technology
title_fullStr CureVac sues BioNTech over mRNA technology
title_full_unstemmed CureVac sues BioNTech over mRNA technology
title_short CureVac sues BioNTech over mRNA technology
title_sort curevac sues biontech over mrna technology
topic News in Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362402/
https://www.ncbi.nlm.nih.gov/pubmed/35945444
http://dx.doi.org/10.1038/s41587-022-01442-8